Researchers have found that a selective GABA inverse agonist can potentiate learning and memory performances in mice with Down's syndrome, reversing learning impairments. The drug also restored normal levels of gene expression in disregulated pathways, suggesting its therapeutic potential.
The concept of food addiction is being debated as a potential mental disorder, with some studies suggesting that certain obese individuals exhibit addictive-like behavior towards food. However, more evidence is needed to support inclusion in the DSM, and experts caution against over-diagnosing disorders.
Researchers suggest targeting the glutamatergic system as a viable target for antidepressant drug development, with potential to rapidly alleviate symptoms of depression. A phase II trial demonstrated a surprisingly rapid antidepressant effect in humans, and further studies indicate extended efficacy.
Researchers found that the extracellular-signal regulated kinase (ERK) pathway is activated in response to chronic drug use and plays a key role in long-lasting behavioral adaptations. ERK activation can be prevented by pharmacological blockade, suggesting a potential target for treating addiction.
Researchers found that epigenetic changes in the brain are associated with Alzheimer's disease, offering potential for novel diagnostic and therapeutic strategies. Epigenetic markers such as DNA methylation and hydroxymethylation increased with age, correlating with AD pathology.
Researchers discovered that the extracellular-signal regulated kinase (ERK) pathway is activated in specific brain areas after exposure to addictive drugs. The study suggests that ERK activation is necessary for long-term synaptic plasticity and may be a suitable target for therapeutic interventions.
The 25th ECNP Congress showcased innovative research on brain disorders, highlighting the importance of neuroscience in prevention and treatment. Key findings included new insights into neural plasticity and its potential for novel treatments.
Researchers propose innovative treatments for alcohol dependence, including motor rehabilitation to increase inhibitory control and environmental enrichment to reduce craving. These approaches aim to improve treatment outcomes and reduce the health and social costs associated with addiction.
Pathological gamblers exhibit abnormally increased reward expectancy, leading to overoptimistic expectations of gambling outcomes. Brain activity studies reveal a higher activation in reward areas when expecting potential wins, contributing to the addictive mechanism.
Suicide rates among young people have risen globally, with males outnumbering females, and are linked to psychiatric disorders, genetic vulnerability, and social factors. The progression from suicidal ideation to self-harm and suicide is not absolute, and early intervention is crucial for prevention.
The Science Media Centre, London, has been awarded the 2012 ECNP Media Award for its outstanding contributions to destigmatising brain disorders. The centre's work highlights the connection between scientific research and public awareness, making complex issues more accessible to a wide audience.
Bertil Fredholm received the 2011 ECNP Neuropsychopharmacology Award for his groundbreaking research on brain adenosine. His work has led to a better understanding of CNS mechanisms in health and disease, with potential applications in treating conditions such as Parkinson's disease, epilepsy, and neuropathic pain.
The 24th ECNP Congress presented landmark studies on the burden of mental disorders in Europe, early intervention in schizophrenia, and sex differences in mental disorders. The event emphasized the need for increased funding and better treatment allocation to address these challenges.
A landmark study reveals that mental disorders have become Europe's largest health challenge, affecting 514 million people. The study highlights a significant treatment gap and calls for increased funding and improved care to address the critical challenges facing mental and neurological disorders.
Bipolar disorder affects 3% of the general population, with significant functional limitations and high rates of psychiatric hospitalization in children and adolescents. The diagnostic criteria for bipolar I disorder in adolescents include mania, euphoria, and irritability, while mixed episodes are common in this age group.
Bertil Fredholm is awarded the 2011 ECNP Neuropsychopharmacology Award for his groundbreaking research on adenosine and its receptors. His work has significantly advanced understanding of CNS mechanisms and provided new targets for drug development across brain disorders.
The 23rd ECNP Congress highlighted the latest discoveries and perspectives in mental health, including gene-environment interactions, circadian rhythms, and brain disease mechanisms. Key take-home messages focused on improving pharmacological and non-drug treatments for mental disorders.
Kaj Blennow receives the 2010 ECNP Neuropsychopharmacology Award for his influential contributions to Alzheimer's disease research. His work focuses on developing laboratory measures for clinical diagnosis and therapy monitoring, holding significant implications for drug development and patient care.
Moussa B.H. Youdim, a renowned neuroscientist, receives the 2010 ECNP Lifetime Achievement Award for his groundbreaking work on neuroprotective therapies for Parkinson's disease and Alzheimer's disease. His research focuses on the role of monoamine oxidase enzymes in neurotransmitter metabolism and brain iron metabolism.
Depression is associated with dysfunction of specific brain regions involved in cognitive control and emotional response, particularly the medial prefrontal cortex. Persistent abnormalities after treatment may indicate a need for complementary therapy.
Research highlights the connection between circadian rhythms and affective disorders, including depression and bipolar disorder. The study found that disrupted circadian rhythms can lead to sleep disturbances, hormonal imbalances, and other health issues.
Schizophrenia is a complex condition characterized by altered brain structure and neurotransmission, leading to symptoms like hallucinations, delusions, and social withdrawal. Delayed access to treatment can result in slower recovery and increased risk of relapse, highlighting the need for early intervention.
Research highlights the importance of gene-environment interactions in understanding psychosis development. Environmental factors such as urbanicity, migration, and cannabis use have been shown to increase risk, while genetic vulnerability plays a role in making individuals more susceptible.
The 23rd ECNP Congress emphasizes the urgent need to address mental disorders, a major challenge for healthcare systems worldwide. Key findings include improved early recognition and diagnosis, as well as comprehensive treatment programs for patients with neurological and mental disorders.
Jean-Pol Tassin's pioneering work identified the disruption of nonadrenaline and serotonin neuron interaction as a key factor in addictive behavior. His research highlights the critical role played by monoamine inhibitors in tobacco addiction.
A study by IMpACT, an international collaboration of researchers, suggests that adult ADHD has a high genetic component. The findings indicate that multiple gene defects contribute to the disorder, with heritability estimates ranging from 60%. This research aims to identify risk genes for ADHD and develop effective treatments.
Schizophrenia is a heterogeneous syndrome with substantial variation in symptomatology and life history. A paradigm shift in research focuses on identifying critical domains of pathology, such as positive and negative symptoms, cognitive impairment, and impaired cognition. This shift aims to improve treatment efficacy by targeting spec...
Studies suggest that genetic factors, particularly those related to monoamine neurotransmitters, may contribute to the development of conduct disorders. Variations in genes encoding enzymes such as MAO-B have been linked to increased risk of antisocial behaviour, with associations strengthening when environmental factors are considered.
The European College of Neuropsychopharmacology emphasizes the need to address mental health issues due to work-related stress and increasing economic troubles. The prevalence of mental disorders is expected to rise, affecting millions worldwide.
Research highlights the potential benefits of antihypertensive treatment on cognitive functions in Alzheimer's disease. Studies show that treating high blood pressure may reduce the incidence of dementia and slow cognitive decline in older adults. However, more studies are needed to confirm these findings.
Research reveals that chronic alcohol consumption alters neural systems in the brain, leading to cognitive deficits and disorders of memory and learning. Dynorphins, a key player in this process, are found to be upregulated in the prefrontal cortex and hippocampus, impairing learning and memory.
Research has identified several genes associated with autism spectrum disorders (ASD), including neuroligins and SHANK3. These genetic findings provide new understanding of the underlying causes of ASD, which affect approximately 60 in 10,000 children worldwide.
Antipsychotics have shown efficacy in treating psychotic disorders and other conditions in children and adolescents, but concerns about metabolic side effects and long-term safety remain. Studies have found increased risk of weight gain, dyslipidemia, and hyperglycaemia with certain antipsychotics.
The ECNP consensus statement on bipolar depression highlights the disease's significant impact on functioning, social relationships, and employment. Early onset of bipolar disorder is associated with a severe burden of disease, particularly during acute depressive episodes.
The adult brain's capacity for neurogenesis is closely tied to stress and depression, with research showing that chronic stress can inhibit new cell growth in the hippocampus. However, antidepressant treatment has been shown to stimulate neurogenesis, suggesting a potential therapeutic target for treating major depressive disorders.
Recent reports suggest antidepressants might exacerbate suicidal tendencies, leading to increased scrutiny of their efficacy. Studies show that depression is a significant risk factor for suicide, with over 60% of completed suicides linked to mood disorders.
Recent advances in autism research have highlighted the importance of genetics in the causes of Autism Spectrum Disorders (ASD). Scientists have identified the first autism disease genes, which may lead to new therapeutic strategies for treatment interventions.
Despite controversy over potential side effects on suicidal behaviour, antidepressant use in western countries correlates with declining suicide mortality. Experts like Professor Erkki Isometsä argue for a balanced view of clinical and epidemiological facts to inform treatment decisions.
The European College of Neuropsychopharmacology consensus statement highlights differences between unipolar and bipolar depression in diagnosis, epidemiology, and treatment. The statement aims to optimize pharmacotherapy and clinical outcomes for patients with bipolar depression.
High blood pressure is linked to an increased risk of dementia, highlighting the potential benefits of antihypertensive treatment. Treatment of hypertension may be a key factor in preventing cognitive decline and dementia.
Chronic stress can affect the adult brain's ability to generate new cells. Stress is associated with reduced neurogenesis, a process critical for developing novel antidepressant drugs.
Researchers identify key role of endogenous opioids in alcoholism-related cognitive impairment. Innovative therapies may improve or prevent alcohol-induced memory problems in patients with alcohol dependence.
The European College of Neuropsychopharmacology (ECNP) offers a unique opportunity for young scientists to expand their knowledge and skills by working on scientific projects. The ECNP Research Grant for Young Scientists provides up to €50,000 funding for projects in neuropsychopharmacology or closely related disciplines.
Research suggests that genetic factors significantly influence human brain structure and intelligence, particularly in regions involved in attention, language, and visual processing. Heritability estimates range from 70-90% for gray matter volume and 40-69% for the hippocampus.
Depression is associated with an increased risk of mortality and adverse cardiovascular outcomes, including heart attacks and strokes. Antidepressant treatments have been shown to be safe and effective in reducing mortality and improving health behaviors in patients with coronary artery disease.
The European College of Neuropsychopharmacology emphasizes the need for early intervention and preventive measures for mental disorders. The vast majority of people with mental disorders remain untreated, particularly in adolescents and young adults.
Researchers have made significant breakthroughs in Alzheimer's disease research, identifying A
Research suggests that computerized working memory training can improve executive functioning and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children. This innovative approach offers a promising therapeutic strategy for alleviating the condition's impact on daily functioning.
The endocannabinoid system has been found to be involved in various physiological processes, including neuroprotection, anxiety, depression, cancer development, vasodilatation, and bone formation. Research suggests that endocannabinoids may have therapeutic potential for diseases such as hepatic encephalopathy.
The opioid system controls pain, reward and addictive behaviors through mu, delta, and kappa receptors. Mice lacking these receptors exhibit altered emotional responses and sensitivity to pain.